WO2015073281A1 - Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor - Google Patents
Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor Download PDFInfo
- Publication number
- WO2015073281A1 WO2015073281A1 PCT/US2014/064202 US2014064202W WO2015073281A1 WO 2015073281 A1 WO2015073281 A1 WO 2015073281A1 US 2014064202 W US2014064202 W US 2014064202W WO 2015073281 A1 WO2015073281 A1 WO 2015073281A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- ghrelin
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to a compound useful for inhibiting ghrelin O-acyl transferase (GOAT), pharmaceutical compositions and methods for treating diseases related to GOAT activity.
- GOAT ghrelin O-acyl transferase
- GOAT belongs to the membrane-bound O-acyl transferase (MBOAT) family of enzymes. It converts desacyl-ghrelin (also known as unacylated ghrelin or UAG) to a biologically active form, acyl-ghrelin (AG), by transferring a fatty acid to the Ser3 residue of the desacylghrelin peptide.
- MBOAT membrane-bound O-acyl transferase
- a GOAT inhibitor is believed to be a useful agent in the treatment of obesity. It is further believed that a GOAT inhibitor may also be useful in reducing weight gain or weight regain as an adjunct to diet and/or exercise, other therapeutic medicinal agents or procedures designed to reducing weight gain or treat obesity. Similarly, a GOAT inhibitor may be useful in treating type 2 diabetes, singly or in combination with other treatments for type 2 diabetes.
- the present invention provides a compound that is a GOAT inhibitor.
- the present invention rovides a compound of formula
- the present invention further provides a compound that is a GOAT inhibitor of formula
- the present invention provides a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients.
- the present invention provides a pharmaceutical composition comprising a compound of the invention and one or more other therapeutic agents.
- a further aspect of the present invention provides a method of reducing weight gain or weight regain or treating type 2 diabetes or obesity comprising administering a compound of the present invention, or a pharmaceutically acceptable salt thereof, to a patient in need thereof.
- the present invention also provides a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in therapy, in particular for reducing weight gain or weight regain or treating type 2 diabetes or obesity. Furthermore, the present invention provides the use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reducing weight gain or weight regain or treating type 2 diabetes or obesity.
- the compound of the present invention is generally effective over a wide dosage range.
- dosages per day fall within the range of about 0.03 to about 150 mg/Kg of body weight.
- dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed while maintaining a favorable benefit/risk profile, and therefore the above dosage range is not intended to limit the scope of the invention in any way.
- the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound or compounds administered, the age, weight, and response of the individual patient, and the severity of the patient's symptoms.
- the term "treating” (or “treat” or “treatment”) as used herein refers to restraining, slowing, stopping, or reversing the progression or severity of an existing symptom, condition or disorder.
- weight gain refers to diminishing the increase in weight of a patient.
- reducing weight regain refers to diminishing the increase in weight of a patient experiencing rebound in weight after weight loss. Weight regain may be due to a rebound effect following cessation of weight loss achieved via diet, exercise, behavior modification, or approved therapies.
- weight gain or weight regain refers to weight gain or weight regain induced by food intake or eating habits and does not refer to non-food related weight gain such as build up of fluids, weight due to water retention, muscle mass, or inflammation.
- a compound of the present invention may react to form pharmaceutically acceptable salts.
- Pharmaceutically acceptable salts and common methodology for preparing them are well known in the art. See, e.g., P. Stahl, et al. Handbook of
- the compound of the invention are comprised of a core that contains at least one chiral center:
- a compound of the present invention is preferably formulated as pharmaceutical compositions administered by a variety of routes.
- Such pharmaceutical compositions and processes for preparing the same are well known in the art. See, e.g., Remington: The Science and Practice of Pharmacy (A. Gennaro, et ah, eds., 21st ed., Mack Publishing Co., 2005). More particularly preferred, is a pharmaceutical composition comprising a compound of the invention re resented by the formula
- Single enantiomers or diastereomers may be prepared beginning with chiral reagents or by stereoselective or stereospecific synthetic techniques. Alternatively, the single enantiomers or diastereomers may be isolated from mixtures by standard chiral chromatographic or crystallization techniques at any convenient point in the synthesis of compounds of the invention. Single enantiomers and diastereomers of compounds of the invention are a preferred embodiment of the invention.
- agents for the treatment of diabetes and/or obesity may be combined with other agents for the treatment of diabetes and/or obesity.
- the compound of the invention, or a pharmaceutically acceptable salt thereof may be coadministered, simultaneously or sequentially, with other effective treatment(s) for diabetes or obesity.
- the compound of the invention, or a pharmaceutically acceptable salt thereof, alone or in combination with other effective treatement(s) may be administered, simultaneously or sequentially, following approved medical procedures such as bariatric surgeries, for example, gastric bypass surgery or adjustable gastric banding procedures.
- the present invention also encompasses intermediates and processes useful for the synthesis of the compound of the present invention.
- variable protecting group may be the same or different in each occurrence depending on the particular reaction conditions and the particular transformations to be performed.
- the protection and deprotection conditions are well known to the skilled artisan. See. e.g., Greene and Wuts, Protective Groups in Organic Synthesis, (T. Greene and P. Wuts, eds., 2d ed. 1991).
- the R or S configuration of the compound of the invention may be determined by standard techniques such as X-ray analysis and correlation with chiral-HPLC retention time.
- the naming of the following Preparations and Example is generally performed using the IUPAC naming feature in MDL Accelrys® Draw version 4.0.NET.
- ACN refers to acetonitrile
- BSA bovine serum albumin
- DCM refers to
- DIPEA N,N-diisopropylethylamine
- DMF dimethylformamide
- DMSO dimethylsulfoxide
- EDTA refers to
- EtOAc ethylenediaminetetraacetic acid
- EtOH ethyl acetate
- EtOH ethanol
- FBS fetal bovine serum
- HRP horseradish peroxidase
- IC50 the concentration of an agent which produces 50% of the maximal response
- IP A refers to isopropyl alcohol
- MeOH refers to methanol
- MTBE refers to methyl tert-butyl ether
- PBS phosphate buffered saline
- RT room temperature
- TAA triethylamine
- TTFA trifluoroacetic acid
- TR refers to time of retention
- THF tetrahydrofuran
- TMB 3,3',5,5'- tetramethylbenzidine.
- GOAT is the principal enzyme that converts UAG to AG.
- ghrelin For reviews of the role of GOAT and ghrelin see: Kristy M. Heppner et al, The ghrelin O-acyltransferase- ghrelin system: a novel regulator of glucose metabolism, Current Opinion in
- Human GOAT gene (Accession number: NM 001100916) is subcloned to pAN51 baculoviral expression vector.
- Baculovirus stock is prepared following the Bac-to-Bac Protocol provided by the vendor, Invitrogen, California, USA. Five mililiters of human GOAT baculoviral stock are added to 500 mL Sf9 cells in HyQ SFX-InsectTM media (HyClone catalog number SH30278.02) at the density of 1 x 10 6 cells per milliliter in a 2 L Erlenmeyer flask. The flask with human GOAT gene infected Sf9 cells is put on a plate shaker at 120 rpm at 28 C for 48 h. After 48 h incubation, cells are centrifuged at l,000xg for 10 min at 4 °C. The cell pellets are collected and stored at -80 °C in a freezer until ready for further processing.
- One gram cell pellets are suspended in 9 mL chilled homogenization buffer (50 mM Tris-HCl, 250 mM sucrose, adjusted to pH 7.5, and sterile filtered through 0.2 ⁇ Millipore filter). The cell suspension is transferred to a Dounce glass homogenizer. Cell pellets are homogenized with 40 strokes on ice. The homogenate is centrifuged at 3,000 rpm in a Beckman swing bucket rotor at 4 °C for 10 min to remove unbroken cells. The supernatant is collected and centrifuged at 40,000 xg for 1 h at 4 °C.
- the resulting membrane pellet is suspended in the homogenization buffer using a Dounce glass homogenizer and stored at -20 °C in the freezer for the assay.
- the suspended membrane is stored in a -80 °C freezer.
- test compounds in DMSO to make up a 0.2 mM stock solution. Serially dilute the stock solution in DMSO to obtain a ten-point dilution curve with final compound concentrations ranging from 10 ⁇ to 0.5 nM in a 96-well round-bottom plate.
- enzyme and substrate solutions in assay buffer (0.02% TweenTM-20 in 50 mM Tris, pH 7.5/250 mM sucrose/1 mg/mL BSA 10 mM EDTA). Add diluted compound (1 ⁇ .) to each well of row A to N of a corresponding low protein binding 384 well plate.
- the data demonstrates that the compound of Example 1 inhibits purified GOAT enzyme activity in vitro. Comparing the change in the ratio of AG to total ghrelin in the compound treated group and that of the vehicle treated group reflects the degree of GOAT enzyme inhibition in vivo, due to the dynamic processing of UAG to AG by the GOAT enzyme. In the in vivo pharmacodynamic studies herein, the levels of AG and UAG in plasma and stomach in the vehicle and compound treated groups are measured by ELISA specifically to these two analytes.
- the total ghrelin level of each sample is computed as the sum of AG and UAG by these ELISA measurements.
- the ratio of AG to total ghrelin is defined by the level of AG in each sample divided by the level of total ghrelin in the same sample.
- the levels of AG, UAG and ratio of AG to total ghrelin in the vehicle treated group is computed and set as 100%. The relative change of these parameters in the compound treated group is then computed to determine the effectiveness of the test compound.
- Weight of Blood (Weight of the tube containing Blood + preservative) - (W eight of the tube containing preservative)
- AG and UAG are extracted from plasma using SEP-PAK® Q 8 column to remove interference prior to performing the ELISA.
- the solid phase extraction of AG and UAG peptides by SEP-PAK® Q 8 columns can be performed on a vacuum manifold (Waters Corp) or using a peristaltic pump.
- the sample SEP-PAK®_column extraction procedure is independently applied to the plasma sample obtained from each individual mouse.
- the general extraction protocol is described as follows.
- TFA TFA
- TweenTM 20 150 ⁇ )( ⁇ 8- ⁇ ).
- Acylghrelin specific antibody (WO 2006/091381 ) or unacylated ghrelin specific antibody (WO 2006/055347) labeled with MSD SULFO- TAG TM (Meso Scale Discovery) are diluted to 0.05 ⁇ g/mL in 0.2 x Blocker Casein containing 0.05% TweenTM 20, named secondary antibody solution. Remove the final wash and add secondary antibody solution (25 ⁇ . to each well) which specifically recognizes AG or UAG. The plates are resealed and incubated for 1 h at RT on a plate shaker before finally washing 3x again with PBS-T (150 ⁇ ).
- MSD Read Buffer 150 ⁇ .
- MSD® SECTOR® Imager 6000 analyzer MSD® SECTOR® Imager 6000 analyzer (Meso Scale Discovery).
- concentrations of acylghrelin or unacylated ghrelin based on the respective standard curve generated by the MSD® software.
- Determine the actual plasma concentration for each sample by multiplying the measured acylghrelin or unacylated ghrelin level by a dilution factor. The dilution factor for each plasma sample is computed with the following equation.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (31)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
UAA201604765A UA118034C2 (en) | 2013-11-14 | 2014-06-11 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
AP2016009189A AP2016009189A0 (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
KR1020167012340A KR101739243B1 (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
EA201690764A EA028550B1 (en) | 2013-11-14 | 2014-11-06 | Ghrelin o-acyl transferase inhibitor |
TN2016000145A TN2016000145A1 (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor. |
ES14802755.0T ES2647790T3 (en) | 2013-11-14 | 2014-11-06 | Piperidyl-ethyl-pyrimidine substituted as an inhibitor of ghrelin O-acyl transferase |
MEP-2017-224A ME02841B (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
NO14802755A NO3068775T3 (en) | 2013-11-14 | 2014-11-06 | |
RS20171067A RS56533B1 (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
SI201430379T SI3068775T1 (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
JP2016531705A JP6159484B2 (en) | 2013-11-14 | 2014-11-06 | Ghrelin O-acyltransferase inhibitor |
AU2014348967A AU2014348967B2 (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin O-acyl transferase inhibitor |
CN201480058584.6A CN105636948B (en) | 2013-11-14 | 2014-11-06 | It is used as the substituted piperidinoethyl pyrimidine of Ge Ruilin O inhibitors |
PL14802755T PL3068775T3 (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
MA39025A MA39025B1 (en) | 2013-11-14 | 2014-11-06 | Piperidyl-ethyl-pyrimidine substituted used as inhibitor of ghrelin o-acyl transferase |
SG11201602953YA SG11201602953YA (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
BR112016009488-3A BR112016009488B1 (en) | 2013-11-14 | 2014-11-06 | substituted piperidyl-ethyl-pyrimidine, its uses, and pharmaceutical composition |
CA2926224A CA2926224C (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
LTEP14802755.0T LT3068775T (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
DK14802755.0T DK3068775T3 (en) | 2013-11-14 | 2014-11-06 | SUBSTITUTED PIPERIDYL-ETHYL-PYRIMIDINE AS GHRELIN-O-ACYL TRANSFERASE INHIBITOR |
EP14802755.0A EP3068775B1 (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
MX2016006223A MX2016006223A (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor. |
NZ718373A NZ718373A (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
DO2016000070A DOP2016000070A (en) | 2013-11-14 | 2016-03-29 | GRELINA INHIBITOR O-ACIL TRANSFERASA |
IL244856A IL244856A (en) | 2013-11-14 | 2016-04-03 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
ZA201602202A ZA201602202B (en) | 2013-11-14 | 2016-04-04 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
CR20160184A CR20160184A (en) | 2013-11-14 | 2016-04-21 | PIPERIDIL-ETIL-PYRIMIDINE REPLACED AS A GHRELIN O-ACIL TRANSFERASA INHIBITOR |
PH12016500895A PH12016500895B1 (en) | 2013-11-14 | 2016-05-13 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
HK16111132.8A HK1222860A1 (en) | 2013-11-14 | 2016-09-22 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor o--- |
CY20171101093T CY1119489T1 (en) | 2013-11-14 | 2017-10-20 | Substituted Pepper-Ethyl-Pyrimidine as Suspension of Ghrelin O-Acyl Transfer |
HRP20171648TT HRP20171648T1 (en) | 2013-11-14 | 2017-10-27 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13382460 | 2013-11-14 | ||
EP13382460.7 | 2013-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015073281A1 true WO2015073281A1 (en) | 2015-05-21 |
Family
ID=49622771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/064202 WO2015073281A1 (en) | 2013-11-14 | 2014-11-06 | Substituted piperidyl-ethyl-pyrimidine as ghrelin o-acyl transferase inhibitor |
Country Status (40)
Country | Link |
---|---|
US (1) | US9035051B1 (en) |
EP (1) | EP3068775B1 (en) |
JP (1) | JP6159484B2 (en) |
KR (1) | KR101739243B1 (en) |
CN (1) | CN105636948B (en) |
AP (1) | AP2016009189A0 (en) |
AR (1) | AR098274A1 (en) |
AU (1) | AU2014348967B2 (en) |
BR (1) | BR112016009488B1 (en) |
CA (1) | CA2926224C (en) |
CL (1) | CL2016001023A1 (en) |
CR (1) | CR20160184A (en) |
CY (1) | CY1119489T1 (en) |
DK (1) | DK3068775T3 (en) |
DO (1) | DOP2016000070A (en) |
EA (1) | EA028550B1 (en) |
ES (1) | ES2647790T3 (en) |
HK (1) | HK1222860A1 (en) |
HR (1) | HRP20171648T1 (en) |
HU (1) | HUE035590T2 (en) |
IL (1) | IL244856A (en) |
JO (1) | JO3302B1 (en) |
LT (1) | LT3068775T (en) |
MA (1) | MA39025B1 (en) |
ME (1) | ME02841B (en) |
MX (1) | MX2016006223A (en) |
NO (1) | NO3068775T3 (en) |
NZ (1) | NZ718373A (en) |
PE (1) | PE20160609A1 (en) |
PH (1) | PH12016500895B1 (en) |
PL (1) | PL3068775T3 (en) |
PT (1) | PT3068775T (en) |
RS (1) | RS56533B1 (en) |
SG (1) | SG11201602953YA (en) |
SI (1) | SI3068775T1 (en) |
TN (1) | TN2016000145A1 (en) |
TW (1) | TWI538677B (en) |
UA (1) | UA118034C2 (en) |
WO (1) | WO2015073281A1 (en) |
ZA (1) | ZA201602202B (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016168225A1 (en) * | 2015-04-15 | 2016-10-20 | Eli Lilly And Company | Ghrelin o-acyl transferase inhibitors |
WO2018024653A1 (en) | 2016-08-05 | 2018-02-08 | Boehringer Ingelheim International Gmbh | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
CN108610337A (en) * | 2018-05-30 | 2018-10-02 | 王丽萍 | A kind of benzo [b] thiophenes and its application in fat and diabetes |
WO2019149660A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
WO2019149657A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
WO2019149658A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
WO2019149659A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
US11518771B2 (en) | 2020-05-22 | 2022-12-06 | Boehringer Ingelheim International Gmbh | Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
US11976082B2 (en) | 2020-05-22 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR104672A1 (en) * | 2015-04-15 | 2017-08-09 | Lilly Co Eli | GRELINA INHIBITORS O-ACILTRANSFERASA |
CN106478519B (en) * | 2016-10-10 | 2018-12-11 | 上海再启生物技术有限公司 | A kind of preparation method of 2- methyl -4- amino -6- chlorine pyrimidine |
CN108558849A (en) * | 2018-05-30 | 2018-09-21 | 王丽萍 | A kind of benzo [b] thiophenes and its application in fat and diabetes |
CN108516971A (en) * | 2018-05-30 | 2018-09-11 | 王丽萍 | A kind of benzo [b] thiophenes and its application in fat and diabetes |
CN108774221A (en) * | 2018-05-30 | 2018-11-09 | 王丽萍 | A kind of GOAT inhibitor and its application in fat and diabetes |
CN108558852A (en) * | 2018-05-30 | 2018-09-21 | 王丽萍 | A kind of GOAT inhibitor and its application in fat and diabetes |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005026211A2 (en) | 2003-09-05 | 2005-03-24 | Eli Lilly And Company | Anti-ghrelin antibodies |
WO2006019577A1 (en) | 2004-07-14 | 2006-02-23 | Eli Lilly And Company | Anti-ghrelin antibodies |
WO2006055347A2 (en) | 2004-11-15 | 2006-05-26 | Eli Lilly And Company | Desacyl ghrelin antibodies and therapeutic uses thereof |
WO2006091381A1 (en) | 2005-02-23 | 2006-08-31 | Eli Lilly And Company | Humanized anti-ghrelin antibodies |
WO2006124490A2 (en) * | 2005-05-17 | 2006-11-23 | Schering Corporation | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia |
WO2007079239A2 (en) * | 2005-12-30 | 2007-07-12 | Acadia Pharmaceuticals Inc. | Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4929601A (en) * | 2000-03-23 | 2001-10-03 | Merck & Co Inc | Substituted piperidines as melanocortin receptor agonists |
WO2006079239A1 (en) | 2005-01-26 | 2006-08-03 | Kistler Holding Ag | Ground insulated piezoelectric sensor for the measurement of acceleration or pressure |
CN101175759A (en) * | 2005-05-17 | 2008-05-07 | 先灵公司 | Nitrogen-containing heterocyclic compounds and methods of use thereof |
JP2011518774A (en) * | 2008-03-20 | 2011-06-30 | フォレスト・ラボラトリーズ・ホールディングス・リミテッド | Novel piperidine derivatives as inhibitors of stearoyl-CoA desaturase |
AR091516A1 (en) * | 2012-06-22 | 2015-02-11 | Actelion Pharmaceuticals Ltd | DERIVATIVES OF 1- [M-CARBOXAMIDO (HETERO) ARIL-METIL] -HETEROCICLIL-CARBOXAMIDA |
-
2014
- 2014-06-11 UA UAA201604765A patent/UA118034C2/en unknown
- 2014-10-30 JO JOP/2014/0316A patent/JO3302B1/en active
- 2014-10-31 TW TW103137938A patent/TWI538677B/en active
- 2014-11-03 AR ARP140104111A patent/AR098274A1/en unknown
- 2014-11-06 KR KR1020167012340A patent/KR101739243B1/en active IP Right Grant
- 2014-11-06 PT PT148027550T patent/PT3068775T/en unknown
- 2014-11-06 BR BR112016009488-3A patent/BR112016009488B1/en active IP Right Grant
- 2014-11-06 CN CN201480058584.6A patent/CN105636948B/en active Active
- 2014-11-06 PE PE2016000620A patent/PE20160609A1/en active IP Right Grant
- 2014-11-06 LT LTEP14802755.0T patent/LT3068775T/en unknown
- 2014-11-06 PL PL14802755T patent/PL3068775T3/en unknown
- 2014-11-06 NO NO14802755A patent/NO3068775T3/no unknown
- 2014-11-06 US US14/534,212 patent/US9035051B1/en active Active
- 2014-11-06 TN TN2016000145A patent/TN2016000145A1/en unknown
- 2014-11-06 SG SG11201602953YA patent/SG11201602953YA/en unknown
- 2014-11-06 NZ NZ718373A patent/NZ718373A/en unknown
- 2014-11-06 SI SI201430379T patent/SI3068775T1/en unknown
- 2014-11-06 MX MX2016006223A patent/MX2016006223A/en active IP Right Grant
- 2014-11-06 AP AP2016009189A patent/AP2016009189A0/en unknown
- 2014-11-06 RS RS20171067A patent/RS56533B1/en unknown
- 2014-11-06 EA EA201690764A patent/EA028550B1/en not_active IP Right Cessation
- 2014-11-06 ES ES14802755.0T patent/ES2647790T3/en active Active
- 2014-11-06 ME MEP-2017-224A patent/ME02841B/en unknown
- 2014-11-06 HU HUE14802755A patent/HUE035590T2/en unknown
- 2014-11-06 DK DK14802755.0T patent/DK3068775T3/en active
- 2014-11-06 EP EP14802755.0A patent/EP3068775B1/en active Active
- 2014-11-06 WO PCT/US2014/064202 patent/WO2015073281A1/en active Application Filing
- 2014-11-06 MA MA39025A patent/MA39025B1/en unknown
- 2014-11-06 JP JP2016531705A patent/JP6159484B2/en active Active
- 2014-11-06 AU AU2014348967A patent/AU2014348967B2/en active Active
- 2014-11-06 CA CA2926224A patent/CA2926224C/en active Active
-
2016
- 2016-03-29 DO DO2016000070A patent/DOP2016000070A/en unknown
- 2016-04-03 IL IL244856A patent/IL244856A/en active IP Right Grant
- 2016-04-04 ZA ZA201602202A patent/ZA201602202B/en unknown
- 2016-04-21 CR CR20160184A patent/CR20160184A/en unknown
- 2016-04-29 CL CL2016001023A patent/CL2016001023A1/en unknown
- 2016-05-13 PH PH12016500895A patent/PH12016500895B1/en unknown
- 2016-09-22 HK HK16111132.8A patent/HK1222860A1/en unknown
-
2017
- 2017-10-20 CY CY20171101093T patent/CY1119489T1/en unknown
- 2017-10-27 HR HRP20171648TT patent/HRP20171648T1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005026211A2 (en) | 2003-09-05 | 2005-03-24 | Eli Lilly And Company | Anti-ghrelin antibodies |
WO2006019577A1 (en) | 2004-07-14 | 2006-02-23 | Eli Lilly And Company | Anti-ghrelin antibodies |
WO2006055347A2 (en) | 2004-11-15 | 2006-05-26 | Eli Lilly And Company | Desacyl ghrelin antibodies and therapeutic uses thereof |
WO2006091381A1 (en) | 2005-02-23 | 2006-08-31 | Eli Lilly And Company | Humanized anti-ghrelin antibodies |
WO2006124490A2 (en) * | 2005-05-17 | 2006-11-23 | Schering Corporation | Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia |
WO2007079239A2 (en) * | 2005-12-30 | 2007-07-12 | Acadia Pharmaceuticals Inc. | Bicyclic nitrogen compounds as modulators of ghrelin receptor and uses thereof |
Non-Patent Citations (8)
Title |
---|
"Remington: The Science and Practice of Pharmacy", 2005, MACK PUBLISHING CO. |
GREENE; WUTS: "Protective Groups in Organic Synthesis", 1991 |
JESUS GUTIERREZ ET AL.: "Ghrelin octanoylation mediated by an orphan lipid transferase", PROC NATL ACAD SCI U S A., vol. 105, no. 17, 29 April 2008 (2008-04-29), pages 6320 - 6325, XP002489029, DOI: doi:10.1073/pnas.0800708105 |
KRISTY M. HEPPNER ET AL.: "Current Opinion in Endocrinology, Diabetes & Obesity", vol. 18, 2011, article "The ghrelin O-acyltransferaseghrelin system: a novel regulator of glucose metabolism", pages: 50 - 55 |
MATTHIAS H. TSCHOP ET AL.: "Gastric O-acyl transferase activates hunger signal to the brain", PROC NATL ACAD SCI U S A., vol. 105, no. 17, 29 April 2008 (2008-04-29), pages 6213 - 6214 |
P. STAHL ET AL.: "Handbook of Pharmaceutical Salts: Properties, Selection and Use", 2011, WILEY-VCH |
PHILLIP A. COLE ET AL.: "Glucose and Weight Control in Mice with a Designed Ghrelin OAcyltransferase Inhibitor", SCIENCE, vol. 330, no. 6011, 17 December 2010 (2010-12-17), pages 1689 - 1692, XP055048732, DOI: doi:10.1126/science.1196154 |
S.M. BERGE ET AL.: "Pharmaceutical Salts", JOURNAL OFPHARMACEUTICAL SCIENCES, vol. 66, no. 1, January 1977 (1977-01-01), XP002675560, DOI: doi:10.1002/jps.2600660104 |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10227310B2 (en) | 2015-04-15 | 2019-03-12 | Eli Lilly And Company | Ghrelin 0-acyl transferase inhibitors |
WO2016168225A1 (en) * | 2015-04-15 | 2016-10-20 | Eli Lilly And Company | Ghrelin o-acyl transferase inhibitors |
AU2017307033B2 (en) * | 2016-08-05 | 2020-11-26 | Boehringer Ingelheim International Gmbh | Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors |
IL264506A (en) * | 2016-08-05 | 2019-02-28 | Boehringer Ingelheim Int | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
WO2018024653A1 (en) | 2016-08-05 | 2018-02-08 | Boehringer Ingelheim International Gmbh | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
US9994591B2 (en) | 2016-08-05 | 2018-06-12 | Boehringer Ingelheim International Gmbh | Oxadiazolopyridine derivates for use as ghrelin O-acyl transferase (GOAT) inhibitors |
KR20190035859A (en) * | 2016-08-05 | 2019-04-03 | 베링거 인겔하임 인터내셔날 게엠베하 | Oxadiazolopyridine derivatives for use as inhibitors of ghrelin O-acyltransferase (GOAT) |
CN109843891A (en) * | 2016-08-05 | 2019-06-04 | 勃林格殷格翰国际有限公司 | Oxadiazoles as motilin O- acyltransferase (GOAT) inhibitor and pyridine derivate |
US10308667B2 (en) | 2016-08-05 | 2019-06-04 | Boehringer Ingelheim International Gmbh | Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
EA037277B1 (en) * | 2016-08-05 | 2021-03-03 | Бёрингер Ингельхайм Интернациональ Гмбх | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
USRE49446E1 (en) | 2016-08-05 | 2023-03-07 | Boehringer Ingelheim International Gmbh | Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
KR102496075B1 (en) | 2016-08-05 | 2023-02-06 | 베링거 인겔하임 인터내셔날 게엠베하 | Oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
TWI749042B (en) * | 2016-08-05 | 2021-12-11 | 德商百靈佳殷格翰國際股份有限公司 | Oxadiazolopyridine derivates for use as ghrelin o-acyl transferase (goat) inhibitors |
CN109843891B (en) * | 2016-08-05 | 2021-11-23 | 勃林格殷格翰国际有限公司 | Oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors |
US11319310B2 (en) | 2018-02-02 | 2022-05-03 | Boehringer Ingelheim International Gmbh | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
US11254688B2 (en) | 2018-02-02 | 2022-02-22 | Boehringer Ingelheim International Gmbh | Benzyl-, (pyridin-3-yl)methyl -or (pyridin-4-yl)-methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyl transferase (GOAT) inhibitors |
CN111655700A (en) * | 2018-02-02 | 2020-09-11 | 勃林格殷格翰国际有限公司 | Benzyl-, (pyridin-3-yl) methyl-or (pyridin-4-yl) methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors |
WO2019149660A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
CN111683951B (en) * | 2018-02-02 | 2023-10-13 | 勃林格殷格翰国际有限公司 | Triazolopyrimidine derivatives useful as ghrelin O-acyltransferase (GOAT) inhibitors |
US11136337B2 (en) | 2018-02-02 | 2021-10-05 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin O-acyl transferase (GOAT) inhibitors |
CN111655699A (en) * | 2018-02-02 | 2020-09-11 | 勃林格殷格翰国际有限公司 | Heterocyclyl substituted oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors |
WO2019149659A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
JP7015396B2 (en) | 2018-02-02 | 2022-02-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Benzyl-, (pyridin-3-yl) methyl-or (pyridin-4-yl) methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors |
CN111683951A (en) * | 2018-02-02 | 2020-09-18 | 勃林格殷格翰国际有限公司 | Triazolopyrimidine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors |
JP2021512113A (en) * | 2018-02-02 | 2021-05-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Benzyl-, (pyridin-3-yl) methyl- or (pyridin-4-yl) methyl-substituted oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors |
CN111655700B (en) * | 2018-02-02 | 2023-07-18 | 勃林格殷格翰国际有限公司 | Oxadiazolopyridine derivatives as ghrelin O-acyltransferase (GOAT) inhibitors |
WO2019149658A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Pyrazole- and indazole-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
US11583532B2 (en) | 2018-02-02 | 2023-02-21 | Boehringer Ingelheim International Gmbh | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors |
WO2019149657A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
CN111655699B (en) * | 2018-02-02 | 2023-07-14 | 勃林格殷格翰国际有限公司 | Heterocyclyl-substituted oxadiazolopyridine derivatives useful as ghrelin O-acyltransferase (GOAT) inhibitors |
CN108610337A (en) * | 2018-05-30 | 2018-10-02 | 王丽萍 | A kind of benzo [b] thiophenes and its application in fat and diabetes |
US11518771B2 (en) | 2020-05-22 | 2022-12-06 | Boehringer Ingelheim International Gmbh | Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
US11976082B2 (en) | 2020-05-22 | 2024-05-07 | Boehringer Ingelheim International Gmbh | Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014348967B2 (en) | Substituted piperidyl-ethyl-pyrimidine as ghrelin O-acyl transferase inhibitor | |
AU2018201896B2 (en) | Salts of an Epidermal Growth Factor Receptor Kinase Inhibitor | |
EP3283473B1 (en) | Ghrelin o-acyl transferase inhibitors | |
EP3283474B1 (en) | Ghrelin o-acyl transferase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14802755 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2926224 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 244856 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: CR2016-000184 Country of ref document: CR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 16104659 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2014348967 Country of ref document: AU Date of ref document: 20141106 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112016009488 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 39025 Country of ref document: MA |
|
ENP | Entry into the national phase |
Ref document number: 20167012340 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201604765 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201690764 Country of ref document: EA Ref document number: IDP00201603174 Country of ref document: ID Ref document number: 000620-2016 Country of ref document: PE Ref document number: MX/A/2016/006223 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12016500895 Country of ref document: PH |
|
ENP | Entry into the national phase |
Ref document number: 2016531705 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014802755 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014802755 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112016009488 Country of ref document: BR Kind code of ref document: A2 Effective date: 20160428 |